Phase II Trial of Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2018
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 11 Jul 2018 Status changed from active, no longer recruiting to completed.
- 14 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2012, according to ClinicalTrials.gov record.